Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 36.1% in February

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 167,500 shares, a decline of 36.1% from the January 31st total of 262,100 shares. Currently, 6.1% of the shares of the company are short sold. Based on an average trading volume of 437,800 shares, the days-to-cover ratio is currently 0.4 days.

Theriva Biologics Stock Performance

Theriva Biologics stock traded down $0.11 during mid-day trading on Monday, reaching $1.33. 27,154 shares of the stock traded hands, compared to its average volume of 183,631. The stock has a market cap of $3.70 million, a PE ratio of -0.04 and a beta of 1.22. Theriva Biologics has a 12-month low of $1.14 and a 12-month high of $17.11.

Wall Street Analysts Forecast Growth

Separately, Maxim Group decreased their target price on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent quarter. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.